The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion

Chiyuki Ueshima¹², Tatsuki R. Kataoka¹, Masahiro Hirata¹, Ayako Furuhata¹, Eiji Suzuki³, Masakazu Toi³, Tatsuaki Tsuruyama¹, Yoshimichi Okayama⁴, and Hironori Haga¹

Abstract

The killer-cell Ig-like receptor (KIR) 2DL4 (CD158d) acts as a receptor for human leukocyte antigen (HLA)-G and is expressed on almost all human natural killer (NK) cells. The expression and function of KIR2DL4 in other hematopoietic cells is poorly understood. Here, we focused on human mast cells, which exhibit cytotoxic activity similar to that of NK cells. KIR2DL4 was detected in all examined human cultured mast cells established from peripheral blood derived from healthy volunteers (PB-mast), the human mast cell line LAD2, and human nonneoplastic mast cells, including those on pathologic specimens. An agonistic antibody against KIR2DL4 decreased KIT-mediated and IgE-triggered secretion and enhanced the granzyme B production by PB-mast and LAD2 cells, by activating Src homology 2–containing protein tyrosine phosphatase (SHP-2). Next, we performed a coculture assay between LAD2 cells and the HLA-G⁺ breast cancer cells, MCF-7 and JEG-3, and showed that KIR2DL4 on LAD2 cells enhanced MMP-9 production and the invasive activity of both cell lines via HLA-G. Immunohistochemical analysis revealed that the direct interaction between HLA-G⁺ breast cancer cells and KIR2DL4⁺ tissue mast cells (observed in 12 of 36 cases; 33.3%) was statistically correlated with the presence of lymph node metastasis or lymph-vascular invasion (observed in 11 of 12 cases; 91.7%; χ² = 7.439; P < 0.01; degrees of freedom, 1) in the clinical samples. These findings suggest that the KIR2DL4 on human mast cells facilitates HLA-G–expressing cancer invasion and the subsequent metastasis. Cancer Immunol Res; 1–10. © 2015 AACR.

Introduction

KIR2DL4 (2DL4/CD158d) is a killer-cell Ig-like receptor (KIR; refs. 1, 2). KIRs are transmembrane proteins that possess two-domain (2D) or three-domain (3D) Ig-like extracellular domains. They are expressed on human natural cultured mast (NK) cells and recognize major histocompatibility complex (MHC) class I molecules (2). In addition, KIRs are categorized according to the presence or absence of immunoreceptor tyrosine–based inhibitory motifs (ITIM), in other words, into KIR with long (L) or short (S) cytoplasmic domains. KIR2DL4 has two Ig-like domains and a long cytoplasmic domain; that is, it contains ITIM motifs, which allow it to transduce inhibitory signals to NK cells (3). The inhibitory signals transduced by KIR2DL4 are mediated by Src homology 2–containing protein tyrosine phosphatase (SHP)-1 and SHP-2 in NK cells (3). Several reports have shown that KIR2DL4 stimulates NK activity and IFNγ secretion (4–7).

Human leukocyte antigen (HLA)-G, which is expressed in fetal tissues during pregnancy and cancer cells, has been identified as the ligand of KIR2DL4 (1, 2). Therefore, it has been suggested that NK cells expressing KIR2DL4 might be involved in the maintenance of pregnancy and in cancer progression (8, 9). Such hypotheses were derived from analyses of NK cells, and, to the best of our knowledge, neither the role(s) nor expression of KIR2DL4 has been examined in human mast cells.

Mast cells are derived from hematopoietic stem cells and are immunocompetent (10). They are activated via KIT and immunoglobulin E (IgE) receptors and secrete Th2 cytokines. In fact, mast cell–derived Th2 cytokines are considered to cause allergic reactions. Furthermore, mast cells have been shown to be involved in both Th17 (11–14) and Th1 responses (11, 15–18). Similar to NK cells, mast cells also secrete the Th1 cytokine IFNγ (17, 19) and exert NK activity via granzyme B (GrB; refs. 20–24).

In this study, we hypothesized that KIR2DL4 plays a functional role in human mast cells, as is the case for NK cells, and so we analyzed KIR2DL4 expression on mast cells.

Materials and Methods

Cells and tissue culture

We prepared human CD34⁺ peripheral blood cell–derived mast cells (PB-mast) and two human mast cell lines (LAD2 and HMC1.2 cells). The PB-mast cells were obtained by culturing CD34⁺ cells in StemPro-34 (Invitrogen) containing recombinant human stem cell factor (rhSCF; Peprotech) and rhIL6 (Peprotech), as described by Kirshenbaum and colleagues (25). The LAD2 cells were cultured in StemPro-34 containing rhSCF (26), and the...
HMC1.2 cells were cultured in Iscove modified Dulbecco’s medium (IMDM) supplemented with 10% fetal bovine serum (FBS; ref. 27).

NK-92, HL60, MCF-7, and JEG-3 cells were purchased from the ATCC. The NK-92 cells were cultured in RPMI-1640 medium supplemented with 10% FBS and rhIL2, and the HL60, MCF-7, and JEG-3 cells were cultured in IMDM supplemented with 10% FBS. All cell lines used were confirmed to be Mycoplasma free. No other authentication assay was performed.

Antibodies, cytokines, and reagents

One agonistic Ab against KIR2DL4 (mouse monoclonal IgG, clone 181703) was purchased from R&D Systems, and the other agonistic anti-KIR2DL4 Ab (mouse monoclonal IgG, clone 33) was from BioLegend. The anti-KIR2DL4 Ab (rabbit IgG, polyclonal, ab154386) used for the immunohistochemical (IHC) examinations and the anti-mast cell tryptase (MCT) Ab (mouse monoclonal IgG, clone AA1) were obtained from Abcam. The anti–HLA-G Ab for IHC examinations (mouse monoclonal IgG, clone 87G) was obtained from ebioscience, and the Fab fragment of the anti–HLA-G Ab (mouse monoclonal IgG, clone 87G) was from Exbio Praha. The isotype control Ab was obtained from BD Biosciences. Fluorescein isothiocyanate (FITC)-labeled anti-mouse IgG Ab (for flow cytometry) was purchased from BD Biosciences, and the secondary Ab (for Western blotting) was peroxidase-labeled anti-rabbit or anti-mouse IgG Ab (Santa Cruz Biotechnology).

KIR2DL4-targeting shRNA lentiviral particles and the associated control particles were purchased from Santa Cruz Biotechnology. The infection and subsequent selection of these viral particles were performed according to the manufacturer’s instructions.

The specific SHP-2 inhibitor PTP Inhibitor V PHPS1 (28) was also purchased from Santa Cruz Biotechnology. We used PHPS1 at a concentration of 10 μmol/L in each experiment (28).

RT-PCR

Mast cells (the PB-mast and LAD2 cells after overnight cytokine depletion, and the HMC1.2 cells; density: 5 × 10⁶ cells in all cases) were added with 600 μL of TRIzol (Invitrogen Life Technologies), lysed by pipetting up and down, and incubated at −20°C. The samples were added with 120 μL of chloroform, vortexed, and centrifuged at 12,000 × g for 15 minutes. The upper phase of each mixture was placed into a new RNeasy column (Qiagen). Total mRNA was then obtained according to the manufacturer’s instructions. Next, 500 ng of each mRNA was reverse transcribed (Super-Script III One-Step RT-PCR System; Invitrogen Life Technologies), and the resultant RT products were used in the KIR typing kit assay (Miltenyi Biotec Inc.) or PCR. The PCR was performed using the following primers, 5'-CCTCCCTGAGTCCTAATCACAG-3' and 5'-ACTCTAGACCAATTCACAG-3', for 35 (Fig. 2A) or 20 cycles (Fig. 6B) of 30 seconds at 94°C (denaturing), 1 minute at 60°C (annealing), and 1 minute at 72°C (extension), followed by a final extension step of 10 minutes at 72°C. (29).

Immunoblotting

Cell lysates were prepared, and the resultant gels were probed for immunoreactive proteins as described previously (30).
anti-mouse IgG Ab (diluted at 1:200; Abcam) and Alexa Fluor 594–conjugated anti-rabbit IgG Ab (diluted at 1:200; Abcam) were added to the cells as secondary antibodies for 1 hour prior to mounting with fluoroshield mounting medium with DAPI (Abcam) after washing three times with PBS. The stained sections were imaged with a BX63 microscope (Olympus) equipped with an ORCA Flash 2.8 digital camera (Hamamatsu Photonics) and with fluorescent filters for Alexa Fluor 488, Alexa Fluor 594, and DAPI. The images were captured and composited using CellSens Dimension imaging software (Olympus); Alexa Fluor 488 signals were red, Alexa Fluor 594 signals were green, and DAPI signals were blue.

**Immunohistochemistry**

IHC was performed essentially as described previously (31). We obtained human tissue samples from 15 cases of cutaneous mastocytosis, 10 cases that were compatible with atopic dermatitis, and 36 cases of breast cancer via mastectomy resections in 2011–2013. All human tissue samples were collected at Kyoto University Hospital (Kyoto, Japan) and were approved for use in this study by the ethical committee of our hospital. Tissue sections were deparaffinized with xylene, rehydrated, and pretreated with 0.3% hydrogen peroxide for 5 minutes, and then steam-heated for 40 minutes. Anti-KIR2DL4 Abs (polyclonal rabbit IgG) were added as primary Ab, and the sections were incubated overnight at 4°C. Staining was performed using the ENVISION kit [horseradish peroxidase (HRP); Dako Cytomation] according to the manufacturer’s instructions. To detect nonneoplastic or neoplastic mast cells, serial sections were treated with anti-MCT Ab and then stained with the ENVISION kit (AEC). In the examinations of breast cancer, serial tissue sections were treated with anti–HLA-G Ab or anti-MCT Ab, and then each section was stained using the ENVISION kit (HRP). In other examinations of breast cancer, a tissue section was stained with anti–HLA-G Ab (mouse IgG, visualized with HRP) followed by staining with anti-MCT Ab (mouse IgG, visualized with AEC). Then, the section was imaged by a BX45 microscope (Olympus) equipped with a DP26 digital camera (Olympus). Then, the same section was stained with anti-KIR2DL4 Ab (rabbit IgG) followed by staining with biotin-conjugated anti-rabbit IgG Ab (Nichirei). FITC-conjugated avidin (Pierce Life Technologies) was added to the section followed by mounting with fluoroshield mounting medium with DAPI. The mounted section was imaged with a BX63 microscope (Olympus) equipped with an ORCA Flash 2.8 digital camera (Hamamatsu Photonics). To assess mast cell–breast cancer cell interaction, we evaluated maximum section of the resected specimens. Direct interactions between mast cells and cancer cells were scored when we observed more than 10 MCT+ cells localized adjacent to cancer cells per 10 high-power field.

**Cell-proliferation assay**

The Cell Counting Kit-8 (CCK-8; Dojindo) was used to evaluate the proliferation of PB-mast, LAD2, and HMC1.2 cells. PB-mast or LAD2 cells were cultured overnight in cytokine-free IMDM supplemented with 10% FBS. Then, PB-mast, LAD2, and HMC1.2

### Figure 2

Anti-KIR2DL4 Abs downregulate KIT-mediated growth and IgE-triggered degranulation of human mast cells. The effects of anti-KIR2DL4 Abs on the proliferation of LAD2 (A), PB-mast (B), and HMC1.2 cells (C). Cells were incubated for 24 hours with control IgG or anti-KIR2DL4 Ab (clone 181703; 10 μg/mL) in the presence or absence of SCF (10 ng/mL; n = 3 in all experiments). Growth was assessed as described in Materials and Methods. Relative values are based on a control IgG value of 100. *P < 0.05, compared with the control IgG value. Effects of anti-KIR2DL4 Ab treatment on degranulation from LAD2 (D) and PB-mast cells (E). Degranulation was evaluated by measuring β-hex release, as described in Materials and Methods. LAD2 or PB-mast cells were sensitized overnight in cytokine-free medium containing biotinylated-human myeloma IgE (100 ng/mL) in the presence of control IgG or anti-KIR2DL4 Ab (clone 181703; 10 μg/mL) and then stimulated with streptavidin (100 ng/mL) without SCF for 30 minutes (n = 3 in all experiments). Relative values are based on a control IgG value of 100. *P < 0.05, compared with the control IgG value.
cells were recultured for 22 hours at a density of 1–3 × 10⁴ cells/100 μL of RPMI-1640 medium containing 10% FCS, together with the control IgG or anti-KIR2DL4 Abs (clone 181703 or 33; 10 μg/mL, each) in the presence or absence of SCF (10 ng/mL). In some experiments, DMSO or PHPS1 was added with the Abs. We added 10 μL of CCK-8 solution for the last 2 hours and estimated the absorbance of the cultures at 450 nm, according to the manufacturer’s instructions.

Degranulation assay
β2-Hexosaminidase (β-hex) release was used as a measure of IgE–triggered degranulation activity (30). LAD2 or PB-mast cells were incubated overnight in cytokine-free StemPro cell culture medium together with biotinylated human myeloma IgE (100 ng/mL; Calbiochem, EMD Biosciences). After washing with HEPES buffer containing 0.04% bovine serum albumin (BSA), cells were re-incubated in the same buffer supplemented with streptavidin (100 ng/mL; Sigma-Aldrich) and the control IgG or anti-KIR2DL4 Ab (clone 181703; 100 μg/mL in both cases) for 30 minutes. The resultant supernatants were aliquoted into 96-well plates for the β-hex assay. Degranulation activity was calculated as follows: degranulation activity (%) = β-hex value for cells cultured with IgG or anti-KIR2DL4 Ab − background β-hex secretion (value for cultured cells alone)/maximum β-hex secretion (value for cells treated with Triton X-100) − background β-hex secretion.

ELISA for GrB
To examine GrB production/secretion, LAD2 or PB-mast cells were cultured overnight in cytokine-free IMDM supplemented with 10% FBS and then resuspended in cytokine-free StemPro-34 or StemPro-34 containing rhSCF. Next, 1 × 10⁶ LAD2 cells (in 100 μL medium per well) were cultured for 6 hours with control IgG or anti-KIR2DL4 Abs (clone 181703 or 33; 10 μg/mL, each). In some experiments, DMSO or PHPS1 was added with the Abs. Fifty-microliter samples of the resultant supernatants were collected and used in an ELISA for GrB (Human Granzyme B Platinum ELISA; eBioscience), according to the manufacturer’s protocol.

Assessment of phospho–mitogen-activated protein kinases
We assessed the amounts of phospho-extracellular signal–regulated kinases (ERK), phosphor–c-Jun N-terminal kinases (JNK), and phospho-p38 using the mitogen–activated protein kinase (MAPK) Family (ERK, p38, JNK) Activation InstantOne ELISA Kit (eBioscience). LAD2 cells were cultured overnight in cytokine-free IMDM supplemented with 10% FBS and then resuspended in cytokine-free StemPro-34. Next, 1 × 10⁵ LAD2 cells (in 1.5-mL tubes) were cultured for 30 minutes with control IgG or anti-KIR2DL4 Abs (clone 181703 or 33; 10 μg/mL, each) in the presence or absence of rhSCF (10 ng/mL). After the cells had been centrifuged, the resultant cell pellets were processed and used for ELISA, which was performed according to the manufacturer’s protocol.

Assessment of the invasive activity of MCF-7 and JEG-3 cells
The invasion of MCF-7 and JEG-3 cells into a gel-based matrix was assessed using Matrigel-coated Transwell polycarbonate membranes (8-μm pores; BD Biosciences). MCF-7 or JEG-3 cells (1 × 10⁵; 100 μL) were added to cytokine-free medium in the upper chamber of the Transwell. Then, 400 μL of StemPro-34 alone, StemPro-34 containing 1 × 10⁵ LAD2 cells that had been transfected with the control vector, or StemPro-34 containing 1 × 10⁵ KIR2DL4-knockdown LAD2 cells were added in the presence or absence of the Fab fragment of anti-HLA-G (clone 87G). After 6 hours of incubation at 37°C, cells that had migrated into the lower chamber were fixed in 4% PFA, stained with Diff-Quick stain (Sysmex), and counted using a microscope.

Assessment of the MMP-9 secretion by MCF-7 and JEG-3 cells
To determine MMP-9 levels, MCF-7 or JEG-3 cells were cultured in a 24-well dish until they were almost confluent. After the culture medium had been removed, 500 μL of StemPro-34 alone, StemPro-34 containing 5 × 10⁵ LAD2 cells that had been transfected with the control vector, or StemPro-34 containing 5 × 10⁵ KIR2DL4-knockdown LAD2 cells were added to each well containing JEG3 cells. After 6 hours of incubation at 37°C, culture supernatant aliquots (100 μL each) were collected and used in an ELISA for MMP-9 (human ELISA kit; Invitrogen), which was performed according to the manufacturer’s protocol.

Statistical analysis
Data in Figs. 2–5 are expressed as the mean ± SE. Differences between groups were examined for statistical significance using the Student t test (Excel; Microsoft). *P values of less than 0.05 were considered to indicate statistical significance. The χ² test was evaluated using Excel (Microsoft).

Results
KIR2DL4 was expressed by human mast cells in vitro and in vivo
We screened human CD34⁺ PB-mast cells (25) and human mast cell lines [LAD2 (26) and HMC1.2 cells (27)] for KIR2DL4 mRNA expression by PCR. The NK92 cells were used as a positive control, and the HL60 cells were used as a negative control (32). As a result, KIR2DL4 mRNA and protein were detected in all three
cell lines, as in the positive control line NK92 (Fig. 1A and B). Next, we examined the localization of KIR2DL4 protein in these human mast cells. In IHC analysis, KIR2DL4 was localized mainly on the surface and in the cytoplasm of PB-mast and LAD2 cells, and mainly in the cytoplasm of HMC1.2 cells (Fig. 1C). In flow cytometry, the PB-mast and LAD2 cells were found to express KIR2DL4 protein on their surfaces, when cells were fixed by 4% PFA (Fig. 1D). Conversely, we did not detect KIR2DL4 protein on the surface of HMC1.2 cells, when cells were fixed by 4% PFA (Fig. 1D).
IHC analysis detected KIR2DL4 in all of the examined nonneoplastic mast cell lines, including skin samples from patients who had been clinically diagnosed with atopic dermatitis (10 of 10 cases; Fig. 1E). In contrast, the neoplastic mast cells in 9 of the 15 skin samples from patients who had been diagnosed with cutaneous mastocytosis lacked KIR2DL4 expression. We did not detect any differences in clinical parameters (age, gender, site, or prognosis) between the KIR2DL4-positive and KIR2DL4-negative mastocytosis cases (data not shown).

Anti-KIR2DL4 Ab downregulated the KIT-mediated and IgE-triggered responses of human mast cells

Administration of anti-KIR2DL4 Ab (clone 181703) decreased the SCF-induced proliferation of LAD2 and PB-mast cells in a dose-dependent manner (Fig. 2A and B). However, when anti-KIR2DL4 Ab was added to HMC1.2 cells, it had no effect on their mutated KIT-associated proliferation (Fig. 2C). We also evaluated the effect of anti-KIR2DL4 Ab on the IgE-triggered degranulation activity of LAD2 and PB-mast cells in a β-hexosaminidase assay. When anti-KIR2DL4 Ab (clone 181703) was administered, the...
degranulation activity of these cells was significantly reduced (Fig. 2D and E).

Anti-KIR2DL4 Ab upregulated the production of GrB from LAD2 cells

We evaluated the effect of anti-KIR2DL4 Ab on GrB secretion from LAD2 and PB-mast cells. GrB secretion from these cells was induced by anti-KIR2DL4 Ab (clone 181703) treatment (Fig. 3A and B).

SHP-2 is involved in both positive and negative effects of anti-KIR2DL4 Abs

Next, we explored the molecular mechanisms by which KIR2DL4 regulates human mast cell activity. Phosphorylation of SHP-2 was investigated by Western blot analysis. Both agonistic Abs against KIR2DL4 (clone 181703 or 33) activated SHP-2 even in the absence of SCF (Fig. 4A). However, we did not observe any marked status changes in SHP-1 (data not shown).

The addition of an SHP-2 inhibitor abrogated the KIR2DL4-induced suppression of KIT-mediated proliferation (Fig. 4B) as well as the KIR2DL4-induced enhancement of GrB secretion (Fig. 4C).

The effects of SHP-2 have been reported to be associated with MAPK activity (33, 34); therefore, we examined the activation of ERK, JNK, and p38. Even in the absence of SCF, these kinases were phosphorylated in LAD2 cells. Administration of anti-KIR2DL4 Abs (clone 181703 or 33) significantly increased the degree of JNK phosphorylation, but not those of ERK and p38, in LAD2 cells (Fig. 4D). However, this increase in JNK phosphorylation was abrogated by an SHP2 inhibitor (Fig. 4D). Taken together, stimulation with anti-KIR2DL4 Abs induced both positive and negative effects by SHP-2 activation in human mast cells, possibly via the SHP-2-induced JNK phosphorylation (summarized in Fig. 4E).

Interaction between KIR2DL4 on human mast cells and HLA-G on cancer cells increased cancer-cell invasive activity

We prepared a coculture system involving the KIR2DL4⁺ human mast cell line LAD2 (Fig. 1B) and the HLA-G⁺ cancer cell lines MCF-7 and JEG-3 (35). To elucidate the role of KIR2DL4 on human mast cells, we prepared KIR2DL4-knockdown LAD2 cells (Fig. 5A). We confirmed that LAD2 cells express KIR2DL4 and no other HLA-G receptors, such as immunoglobulin-like transcript (ILT) 2 and ILT4 (data not shown). We checked the cytotoxic activity of LAD2 cells against MCF-7 or JEG-3 cells at the same cell number (E:T ratio = 1:1); LAD2 cells did not have a significant effect on the viability of these target cells at this E:T ratio (data not shown). Next, a two-chamber invasion assay was performed. Results from the assay revealed that coculture with LAD2 cells significantly enhanced the invasive activity of MCF-7 and JEG-3 cells (Fig. 5B). We checked the secretion of MMP-9, which is known to be produced by human mast cells and to play an important role in cancer invasion (36, 37). Stimulation of KIR2DL4 induced MMP-9 secretion from mock LAD2 cells, but not from KIR2DL4-knockdown LAD2 cells (Fig. 5C). Coculture of MCF-7 or JEG-3 cells with LAD2 cells in 24-well dish enhanced the number of invading cells and the magnitude of MMP-9 production was also decreased significantly (Fig. 5B and C). Treatment with Fab fragment of anti–HLA-G (clone 87G) also significantly decreased the number of invading cells and the magnitude of

![Figure 6. Interaction between KIR2DL4⁺ mast cells and HLA-G⁺ breast cancer cells was associated with invasion and metastasis in the clinical samples. IHC of representative cases. A, specimens stained with hematoxylin and eosin (H&E), HLA-G, MCT (a mast-cell marker), and KIR2DL4, in serial sections. Arrowheads show KIR2DL4⁺ mast cells interacting with HLA-G⁺ breast cancer cells. Bar, 100 μm. B, sections were stained with HLA-G (brown) and MCT (red), followed by staining with anti-KIR2DL4 Ab (green) and DAPI (blue).](cancerimmunolres.aacrjournals.org/article-figures/00075.jpg)
Next, we evaluated the association of KIR2DL4 on human mast cells and HLA-G expression in breast cancer cells. Antibodies against HLA-G were detected in 27 cases (75%) by IHC. Direct interaction between KIR2DL4+ breast cancer cells was observed in 11 of 36 cases (30.6%); representative cases are shown in Fig. 6. Of the 12 cases with direct interaction between KIR2DL4+ mast cells and HLA-G+ breast cancer cells, 11 cases (91.7%) were accompanied with lymph node metastasis or with lymph-vessel invasion. The $\chi^2$ test showed statistically significant correlation between the presence of KIR2DL4+ mast cells—HLA-G+ breast cancer cell interaction and the presence of lymph node metastasis or lymph-vessel invasion ($\chi^2 = 7.424; P < 0.01;\) degrees of freedom, 1).

**Discussion**

In this study, we found that KIR2DL4 was expressed in all human nonneoplastic mast cells examined, and regulated human cultured mast cells positively and negatively. In addition, the KIR2DL4 expressed on human mast cells enhanced the invasive activity of HLA-G+ breast cancer cells.

All nonneoplastic human mast cells (PB-mast and tissue mast cells included in the skin samples) examined expressed KIR2DL4 protein, as was found for NK cells (29). In addition, in nonneoplastic mast cells obtained by culturing CD4+/CD8+/CD11b+/CD14+/CD68+/CD19+ cells in methylcellulose medium supplemented with rhSCF and rhIL6, or human mast cells obtained by culturing CD34+ cells derived from peripheral blood cells in the same medium, or human mast cells collected and established from surgically resected lung tissue using anti-KIT Ab (data not shown; refs. 38, 39). Nevertheless, we also found a lack of KIR2DL4 protein expression on the human neoplastic mast cell line HMC1.2 and some neoplastic mast cell samples from patients with cutaneous mastocytosis. These observations suggest that a lack of KIR2DL4 protein expression could be a marker of neoplastic changes in mast cells. KIR2DL4 expression suppressed the proliferation of human nonneoplastic mast cells; therefore, KIR2DL4 deficiency might aid the uncontrollable proliferation of neoplastic mast cells. However, we could not detect any clinical differences between cases of cutaneous mastocytosis involving KIR2DL4+ and KIR2DL4− mast cells. This might be because cutaneous mastocytosis is too indolent for significant differences in clinical parameters to be detected (40).

Structurally, KIR2DL4 is an inhibitory receptor (1, 2); therefore, our finding that KIR2DL4 suppresses KIT-mediated interaction between KIR2DL4+ mast cells and HLA-G+ breast cancer cells is associated with invasion and metastasis in the clinical samples

Next, we evaluated the association of KIR2DL4 on human mast cells and the invasive phenotypes of cancer cells using clinical samples. Thirty-six samples resected by mastectomy during the period of 2011 to 2013 at our hospital were prepared for this evaluation (summarized in Table 1). In all cases examined, KIR2DL4+ human tissue mast cells were detected. Breast cancer cells were positive for HLA-G in 27 cases (75%) by IHC. Direct interaction between KIR2DL4+ mast cells and HLA-G+ breast cancer cells was observed in 12 of 36 cases (33.3%); representative cases are shown in Fig. 6. Of the 12 cases with direct interaction between KIR2DL4+ mast cells and HLA-G+ breast cancer cells, 11 cases (91.7%) were accompanied with lymph node metastasis or with lymph-vessel invasion. The $\chi^2$ test showed statistically significant correlation between the presence of KIR2DL4+ mast cells—HLA-G+ breast cancer cell interaction and the presence of lymph node metastasis or lymph-vessel invasion ($\chi^2 = 7.424; P < 0.01;\) degrees of freedom, 1).

**Table 1. Clinical parameters of the examined breast cancer cases**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>HLA-G+ (27 cases)</th>
<th>HLA-G− (9 cases)</th>
<th>Total (36 cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cell–cancer cell interaction</td>
<td>12 (44.4%)</td>
<td>4 (44.4%)</td>
<td>16 (44.4%)</td>
</tr>
<tr>
<td>(with ly+ and/or pN+)</td>
<td>11/2</td>
<td>1/4</td>
<td>12/6</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27 (100%)</td>
<td>9 (100%)</td>
<td>36 (100%)</td>
</tr>
<tr>
<td>Age, y</td>
<td>59.4 ± 2.60</td>
<td>59.3 ± 3.03</td>
<td>59.4 ± 2.07</td>
</tr>
<tr>
<td>Surgical procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mastectomy</td>
<td>27 (100%)</td>
<td>9 (100%)</td>
<td>36 (100%)</td>
</tr>
<tr>
<td>pT stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(y)pT1</td>
<td>13 (48.1%)</td>
<td>5 (55.6%)</td>
<td>18 (50.0%)</td>
</tr>
<tr>
<td>(y)pT2</td>
<td>12 (44.4%)</td>
<td>3 (33.3%)</td>
<td>15 (41.7%)</td>
</tr>
<tr>
<td>(y)pT3</td>
<td>2 (7.4%)</td>
<td>1 (11.1%)</td>
<td>3 (8.3%)</td>
</tr>
<tr>
<td>pN stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(y)pN0</td>
<td>9 (33.3%)</td>
<td>6 (66.7%)</td>
<td>15 (41.7%)</td>
</tr>
<tr>
<td>(y)pN1</td>
<td>15 (48.1%)</td>
<td>3 (33.3%)</td>
<td>18 (44.1%)</td>
</tr>
<tr>
<td>(y)pN2</td>
<td>1 (3.7%)</td>
<td>0 (0%)</td>
<td>1 (2.8%)</td>
</tr>
<tr>
<td>(y)pN3</td>
<td>4 (14.8%)</td>
<td>0 (0%)</td>
<td>4 (11.1%)</td>
</tr>
<tr>
<td>Lymphvascular invasion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>5 (18.5%)</td>
<td>0 (0%)</td>
<td>5 (13.9%)</td>
</tr>
<tr>
<td>Negative</td>
<td>22 (81.5%)</td>
<td>9 (100%)</td>
<td>31 (86.1%)</td>
</tr>
<tr>
<td>Preoperative chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>8 (29.6%)</td>
<td>2 (22.2%)</td>
<td>10 (27.8%)</td>
</tr>
<tr>
<td>Absent</td>
<td>19 (70.4%)</td>
<td>7 (77.8%)</td>
<td>26 (72.2%)</td>
</tr>
<tr>
<td>Histologic grading</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>6 (22.2%)</td>
<td>2 (22.2%)</td>
<td>8 (22.2%)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>12 (44.4%)</td>
<td>3 (33.3%)</td>
<td>15 (41.7%)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>9 (33.3%)</td>
<td>4 (44.4%)</td>
<td>13 (36.1%)</td>
</tr>
<tr>
<td>Molecular subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luminal A</td>
<td>10 (37.0%)</td>
<td>5 (55.6%)</td>
<td>15 (41.7%)</td>
</tr>
<tr>
<td>Luminal B</td>
<td>9 (33.3%)</td>
<td>2 (22.2%)</td>
<td>11 (30.6%)</td>
</tr>
<tr>
<td>HER2</td>
<td>1 (3.7%)</td>
<td>0 (0%)</td>
<td>1 (2.8%)</td>
</tr>
<tr>
<td>Luminal-HER2</td>
<td>4 (14.8%)</td>
<td>0 (0%)</td>
<td>4 (11.1%)</td>
</tr>
<tr>
<td>Triple negative</td>
<td>3 (11.1%)</td>
<td>2 (22.2%)</td>
<td>5 (13.9%)</td>
</tr>
</tbody>
</table>
and IgE-triggered responses of LAD2 and PB-mast cells makes sense. Mast cells express various inhibitory receptors that can suppress KIT-mediated and/or IgE-triggered responses (30, 31, 41–45). These receptors have inhibitory effects by activating nonreceptor-type phosphatases, such as SHP-1 and SHP-2. KIR2DL4 belongs to this group of inhibitory receptors and acts by activating SHP-2. Accordingly, anti-KIR2DL4 Abs are expected to be a useful tool for treating allergic conditions mediated by mast cells, as has been found for Abs for other receptors.

We observed that the invasive properties of HLA-G+ breast cancer cells were enhanced by mast cells. Some HLA-G+ neoplasms, including breast cancers, were associated with metastatic phenotypes, and this observation has been explained by immune escape from NK cells and by induction of immune-suppressive regulatory T cells (46, 47). Our current data provide another explanation for these reports; that is, mast cells are involved in the HLA-G–KIR2DL4 axis and are able to enhance the invasive properties of cancer cells. Mast cell infiltration has been reported to be associated with invasive or metastatic phenotypes of various cancers (48). Therefore, the interaction of HLA-G on cancer cells and KIR2DL4 on human mast cells would be expected to exist in such invasive or metastatic cases as we have demonstrated in this study.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References


The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion

Chiyuki Ueshima, Tatsuki R. Kataoka, Masahiro Hirata, et al.


Updated version  Access the most recent version of this article at: doi:10.1158/2326-6066.CIR-14-0199

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.